Is SGMO or ENGN more profitable?

enGene has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. enGene's return on equity of -56.06% beat Sangamo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sangamo Therapeutics -310.81% -2,662.06% -132.12% enGene N/A -56.06% -45.64%

Is GNLX or SGMO more profitable?

Genelux has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. Genelux's return on equity of -205.85% beat Sangamo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Genelux N/A -205.85% -138.79% Sangamo Therapeutics -310.81% -2,662.06% -132.12%

Do analysts recommend AADI or SGMO?

Sangamo Therapeutics has a consensus target price of $5.50, suggesting a potential upside of 7,332.43%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sangamo Therapeutics is more favorable than Aadi Bioscience. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aadi Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Sangamo Therapeutics 2 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.75

Sangamo Therapeutics (SGMO) Competitors

$0.07 0.00 (0.00%)

As of 09/4/2026

Compare

SGMO vs. ENGN, GNLX, ANIX, RANI, and AADI

Should you buy Sangamo Therapeutics stock or one of its competitors? Sangamo Therapeutics's main competitors and comparable companies include enGene (ENGN), Genelux (GNLX), Anixa Biosciences (ANIX), Rani Therapeutics (RANI), and Aadi Bioscience (AADI). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Sangamo Therapeutics compare to enGene?

Sangamo Therapeutics (NASDAQ:SGMO) and enGene (NASDAQ:ENGN) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

56.9% of Sangamo Therapeutics shares are owned by institutional investors. Comparatively, 64.2% of enGene shares are owned by institutional investors. 4.1% of Sangamo Therapeutics shares are owned by company insiders. Comparatively, 10.5% of enGene shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Sangamo Therapeutics currently has a consensus target price of $5.50, indicating a potential upside of 7,332.43%. enGene has a consensus target price of $11.05, indicating a potential upside of 506.89%. Given Sangamo Therapeutics' higher possible upside, equities analysts clearly believe Sangamo Therapeutics is more favorable than enGene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75
enGene	2 Sell rating(s)	8 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.14

Sangamo Therapeutics has a beta of 1.3, meaning that its share price is 30% more volatile than the broader market. Comparatively, enGene has a beta of -0.28, meaning that its share price is 128% less volatile than the broader market.

In the previous week, enGene had 22 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 22 mentions for enGene and 0 mentions for Sangamo Therapeutics. Sangamo Therapeutics' average media sentiment score of 0.00 beat enGene's score of -0.15 indicating that Sangamo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Sangamo Therapeutics	Neutral
enGene	Neutral

enGene has lower revenue, but higher earnings than Sangamo Therapeutics. enGene is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A
enGene	N/A	N/A	-$117.30M	-$2.17	N/A

enGene has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. enGene's return on equity of -56.06% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%
enGene	N/A	-56.06%	-45.64%

Summary

enGene beats Sangamo Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Sangamo Therapeutics compare to Genelux?

Genelux (NASDAQ:GNLX) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Genelux currently has a consensus price target of $18.00, indicating a potential upside of 637.70%. Sangamo Therapeutics has a consensus price target of $5.50, indicating a potential upside of 7,332.43%. Given Sangamo Therapeutics' higher possible upside, analysts clearly believe Sangamo Therapeutics is more favorable than Genelux.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genelux	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Genelux has higher earnings, but lower revenue than Sangamo Therapeutics. Genelux is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genelux	$10K	11,038.56	-$32.15M	-$0.86	N/A
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A

In the previous week, Genelux had 6 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 6 mentions for Genelux and 0 mentions for Sangamo Therapeutics. Genelux's average media sentiment score of 0.69 beat Sangamo Therapeutics' score of 0.00 indicating that Genelux is being referred to more favorably in the media.

Company	Overall Sentiment
Genelux	Positive
Sangamo Therapeutics	Neutral

37.3% of Genelux shares are owned by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are owned by institutional investors. 7.5% of Genelux shares are owned by insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Genelux has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. Genelux's return on equity of -205.85% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genelux	N/A	-205.85%	-138.79%
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%

Genelux has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market. Comparatively, Sangamo Therapeutics has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market.

Summary

Genelux beats Sangamo Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Sangamo Therapeutics compare to Anixa Biosciences?

Anixa Biosciences (NASDAQ:ANIX) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

Anixa Biosciences has a beta of 0.51, meaning that its stock price is 49% less volatile than the broader market. Comparatively, Sangamo Therapeutics has a beta of 1.3, meaning that its stock price is 30% more volatile than the broader market.

Anixa Biosciences has higher earnings, but lower revenue than Sangamo Therapeutics. Anixa Biosciences is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anixa Biosciences	$210K	497.34	-$10.93M	-$0.31	N/A
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A

In the previous week, Anixa Biosciences had 3 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 3 mentions for Anixa Biosciences and 0 mentions for Sangamo Therapeutics. Anixa Biosciences' average media sentiment score of 0.00 equaled Sangamo Therapeutics'average media sentiment score.

Company	Overall Sentiment
Anixa Biosciences	Neutral
Sangamo Therapeutics	Neutral

Anixa Biosciences currently has a consensus target price of $8.50, indicating a potential upside of 176.87%. Sangamo Therapeutics has a consensus target price of $5.50, indicating a potential upside of 7,332.43%. Given Sangamo Therapeutics' higher possible upside, analysts plainly believe Sangamo Therapeutics is more favorable than Anixa Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anixa Biosciences	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Anixa Biosciences has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. Anixa Biosciences' return on equity of -71.12% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anixa Biosciences	N/A	-71.12%	-62.88%
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%

29.1% of Anixa Biosciences shares are held by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are held by institutional investors. 26.4% of Anixa Biosciences shares are held by insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Summary

Anixa Biosciences beats Sangamo Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Sangamo Therapeutics compare to Rani Therapeutics?

Rani Therapeutics (NASDAQ:RANI) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, risk, media sentiment, analyst recommendations, earnings, valuation, dividends and institutional ownership.

Rani Therapeutics presently has a consensus target price of $8.75, indicating a potential upside of 911.21%. Sangamo Therapeutics has a consensus target price of $5.50, indicating a potential upside of 7,332.43%. Given Sangamo Therapeutics' higher probable upside, analysts clearly believe Sangamo Therapeutics is more favorable than Rani Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rani Therapeutics	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

Rani Therapeutics has higher earnings, but lower revenue than Sangamo Therapeutics. Rani Therapeutics is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rani Therapeutics	$1.63M	74.00	-$29.67M	-$0.27	N/A
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A

In the previous week, Rani Therapeutics had 1 more articles in the media than Sangamo Therapeutics. MarketBeat recorded 1 mentions for Rani Therapeutics and 0 mentions for Sangamo Therapeutics. Rani Therapeutics' average media sentiment score of 0.00 equaled Sangamo Therapeutics'average media sentiment score.

Company	Overall Sentiment
Rani Therapeutics	Neutral
Sangamo Therapeutics	Neutral

Rani Therapeutics has a beta of 0.69, indicating that its share price is 31% less volatile than the broader market. Comparatively, Sangamo Therapeutics has a beta of 1.3, indicating that its share price is 30% more volatile than the broader market.

Rani Therapeutics has a net margin of 0.00% compared to Sangamo Therapeutics' net margin of -310.81%. Rani Therapeutics' return on equity of -104.60% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rani Therapeutics	N/A	-104.60%	-65.17%
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%

30.2% of Rani Therapeutics shares are held by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are held by institutional investors. 26.7% of Rani Therapeutics shares are held by insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Rani Therapeutics beats Sangamo Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Sangamo Therapeutics compare to Aadi Bioscience?

Aadi Bioscience (NASDAQ:AADI) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability, media sentiment and analyst recommendations.

In the previous week, Aadi Bioscience's average media sentiment score of 0.00 equaled Sangamo Therapeutics'average media sentiment score.

Company	Overall Sentiment
Aadi Bioscience	Neutral
Sangamo Therapeutics	Neutral

Aadi Bioscience has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market. Comparatively, Sangamo Therapeutics has a beta of 1.3, suggesting that its stock price is 30% more volatile than the broader market.

Aadi Bioscience has higher earnings, but lower revenue than Sangamo Therapeutics. Aadi Bioscience is trading at a lower price-to-earnings ratio than Sangamo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aadi Bioscience	$25.07M	4.53	-$65.76M	-$2.35	N/A
Sangamo Therapeutics	$39.55M	0.78	-$122.93M	-$0.38	N/A

Aadi Bioscience has a net margin of -246.06% compared to Sangamo Therapeutics' net margin of -310.81%. Aadi Bioscience's return on equity of -71.87% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aadi Bioscience	-246.06%	-71.87%	-57.28%
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%

Sangamo Therapeutics has a consensus target price of $5.50, suggesting a potential upside of 7,332.43%. Given Sangamo Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Sangamo Therapeutics is more favorable than Aadi Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aadi Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

52.1% of Aadi Bioscience shares are owned by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are owned by institutional investors. 37.3% of Aadi Bioscience shares are owned by company insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Sangamo Therapeutics beats Aadi Bioscience on 8 of the 14 factors compared between the two stocks.

Get Sangamo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SGMO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SGMO vs. The Competition

Export

Metric	Sangamo Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$30.66M	$4.00B	$7.25B	$12.91B
Dividend Yield	N/A	3.60%	2.54%	9.13%
P/E Ratio	-0.17	12.65	273.26	25.43
Price / Sales	0.78	1,359.63	629.56	95.06
Price / Cash	N/A	45.00	28.92	35.62
Price / Book	-1.85	15.99	10.84	6.39
Net Income	-$122.93M	-$22.85M	$3.49B	$358.69M
7 Day Performance	N/A	1.37%	1.15%	1.17%
1 Month Performance	N/A	5.93%	4.29%	-0.23%
1 Year Performance	N/A	49.10%	23.83%	13.72%

Sangamo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SGMO Sangamo Therapeutics	1.0367 of 5 stars	$0.07 flat	$5.50 +7,332.4%	N/A	$30.66M	$39.55M	N/A	480
ENGN enGene	3.4902 of 5 stars	$1.84 +0.8%	$11.05 +500.3%	-64.9%	$122.25M	N/A	N/A	31	Earnings Report Upcoming Earnings
GNLX Genelux	2.3732 of 5 stars	$2.62 -1.5%	$18.00 +587.0%	-27.6%	$120.35M	$10K	N/A	10
ANIX Anixa Biosciences	3.7806 of 5 stars	$3.35 -3.7%	$8.50 +153.7%	+3.4%	$118.40M	$210K	N/A	5	Upcoming Earnings
RANI Rani Therapeutics	2.6059 of 5 stars	$0.85 +1.6%	$8.75 +924.8%	+72.3%	$117.09M	$1.63M	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SGMO) was last updated on 9/8/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sangamo Therapeutics (SGMO) Competitors

SGMO vs. ENGN, GNLX, ANIX, RANI, and AADI

How does Sangamo Therapeutics compare to enGene?

Summary

How does Sangamo Therapeutics compare to Genelux?

Summary

How does Sangamo Therapeutics compare to Anixa Biosciences?

Summary

How does Sangamo Therapeutics compare to Rani Therapeutics?

Summary

How does Sangamo Therapeutics compare to Aadi Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMO vs. The Competition

Sangamo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sangamo Therapeutics (SGMO) Competitors

SGMO vs. ENGN, GNLX, ANIX, RANI, and AADI

How does Sangamo Therapeutics compare to enGene?

Do institutionals and insiders believe in SGMO or ENGN?

Do analysts recommend SGMO or ENGN?

Which has more volatility & risk, SGMO or ENGN?

Does the media refer more to SGMO or ENGN?

Which has higher earnings & valuation, SGMO or ENGN?

Is SGMO or ENGN more profitable?

Summary

How does Sangamo Therapeutics compare to Genelux?

Do analysts recommend GNLX or SGMO?

Which has higher earnings & valuation, GNLX or SGMO?

Does the media prefer GNLX or SGMO?

Do institutionals & insiders believe in GNLX or SGMO?

Is GNLX or SGMO more profitable?

Which has more risk and volatility, GNLX or SGMO?

Summary

How does Sangamo Therapeutics compare to Anixa Biosciences?

Which has more risk & volatility, ANIX or SGMO?

Which has better valuation & earnings, ANIX or SGMO?

Does the media refer more to ANIX or SGMO?

Do analysts recommend ANIX or SGMO?

Is ANIX or SGMO more profitable?

Do insiders & institutionals hold more shares of ANIX or SGMO?

Summary

How does Sangamo Therapeutics compare to Rani Therapeutics?

Do analysts prefer RANI or SGMO?

Which has higher earnings and valuation, RANI or SGMO?

Does the media refer more to RANI or SGMO?

Which has more volatility & risk, RANI or SGMO?

Is RANI or SGMO more profitable?

Do insiders and institutionals hold more shares of RANI or SGMO?

Summary

How does Sangamo Therapeutics compare to Aadi Bioscience?

Does the media prefer AADI or SGMO?

Which has more risk and volatility, AADI or SGMO?

Which has preferable valuation and earnings, AADI or SGMO?

Is AADI or SGMO more profitable?

Do analysts recommend AADI or SGMO?

Do institutionals and insiders have more ownership in AADI or SGMO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SGMO vs. The Competition

Sangamo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools